-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Nanjing Chia Tai Tianqing’s sofosbuvir tablets and lenvatinib mesylate capsules for production under the new registration classification entered the administrative examination and approval stage, and they are expected to win the second and third domestic products respectively
Source: official website of the State Drug Administration
Sofosbuvir is the world’s first NS5B polymerase inhibitor developed by Gilead, also known as "Gee Generation".
According to data from Meinenet, Sofosbuvir tablets have not yet opened in the domestic market.
Production status of new classification of Sofosbuvir tablets
Source: One-click search on Mi Nei.
Seven domestic companies have submitted applications for the listing of Sofosbuvir tablets with imitations of category 3 or 4, and Kain Technology’s products were approved for listing in March 2020, making it the first imitation in China; Nanjing Chia Tai Tianqing’s products have recently stepped up Entering the administrative examination and approval stage, it is expected to win the second domestically produced company
Source: official website of the State Drug Administration
Lenvatinib is a multi-target receptor tyrosine kinase inhibitor developed by Eisai/Mersk.
The original research product was approved for import in September 2018, becoming the second domestically marketed first-line targeted therapy for liver cancer; the second indication was approved in November 2020 for the treatment of thyroid cancer
According to data from Menet.
Sales of lenvatinib at the terminal of physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
New classification of lenvatinib mesylate capsules under review
Source: Meinenet MED2.
At present, 12 domestic companies’ lenvatinib generic drugs have been listed on the market.
Source: Mi Nei.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
